Matches in Wikidata for { <http://www.wikidata.org/entity/Q97411772> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q97411772 description "article scientifique publié en 2020" @default.
- Q97411772 description "artículu científicu espublizáu en xunetu de 2020" @default.
- Q97411772 description "scientific article published on 03 July 2020" @default.
- Q97411772 description "wetenschappelijk artikel" @default.
- Q97411772 description "наукова стаття, опублікована 3 липня 2020" @default.
- Q97411772 name "Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs" @default.
- Q97411772 name "Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs" @default.
- Q97411772 type Item @default.
- Q97411772 label "Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs" @default.
- Q97411772 label "Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs" @default.
- Q97411772 prefLabel "Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs" @default.
- Q97411772 prefLabel "Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs" @default.
- Q97411772 P1433 Q97411772-B7E4A16B-27C4-4A91-AA9A-6D20010E27AC @default.
- Q97411772 P1476 Q97411772-22CCF44A-162A-41D1-81B1-A006BA5CA1D1 @default.
- Q97411772 P2093 Q97411772-823CAA35-E35C-4844-A8A0-DD84EB5DFE0D @default.
- Q97411772 P275 Q97411772-579cb826-00f6-487e-835f-0122b1e7c41b @default.
- Q97411772 P304 Q97411772-4E94E171-A12B-4A22-A7A7-DD1AD7530D0D @default.
- Q97411772 P31 Q97411772-72D616FD-39AE-4B8E-93CF-25A10D899454 @default.
- Q97411772 P356 Q97411772-EE875FC0-BC7C-47B1-8634-25021534B4C9 @default.
- Q97411772 P407 Q97411772-97DA1F98-EC25-46A4-B6EF-A0EC09C4A3A2 @default.
- Q97411772 P433 Q97411772-80B228B0-31B6-4D78-9FC6-AE46EC64D5C1 @default.
- Q97411772 P478 Q97411772-F6779AE8-24F0-4A43-B718-7D70D1E2DF81 @default.
- Q97411772 P50 Q97411772-BB6BC887-5C76-47EE-A508-B2737D6C5C90 @default.
- Q97411772 P577 Q97411772-1F8685B2-6179-4B10-B26B-FB0A2A3C6A87 @default.
- Q97411772 P577 Q97411772-79859989-F155-4627-B4AA-898465CEAA34 @default.
- Q97411772 P6216 Q97411772-c3c96e2a-6cff-4056-97a5-a4977789af4d @default.
- Q97411772 P698 Q97411772-5F95CEA7-400B-463E-8F00-389681ABC9BB @default.
- Q97411772 P932 Q97411772-BDF0E315-035D-4CF2-9222-C40115082D80 @default.
- Q97411772 P953 Q97411772-EAB797BB-717C-4B94-9FC2-6648376CAA21 @default.
- Q97411772 P356 IJMS21134741 @default.
- Q97411772 P698 32635199 @default.
- Q97411772 P1433 Q3153277 @default.
- Q97411772 P1476 "Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs" @default.
- Q97411772 P2093 "José Pedro Cerón-Carrasco" @default.
- Q97411772 P275 Q20007257 @default.
- Q97411772 P304 "4741" @default.
- Q97411772 P31 Q13442814 @default.
- Q97411772 P356 "10.3390/IJMS21134741" @default.
- Q97411772 P407 Q1860 @default.
- Q97411772 P433 "13" @default.
- Q97411772 P478 "21" @default.
- Q97411772 P50 Q47697002 @default.
- Q97411772 P577 "2020-01-01T00:00:00Z" @default.
- Q97411772 P577 "2020-07-03T00:00:00Z" @default.
- Q97411772 P6216 Q50423863 @default.
- Q97411772 P698 "32635199" @default.
- Q97411772 P932 "7369966" @default.
- Q97411772 P953 4741 @default.